The Myelodysplastic Syndromes Channel on VJHemOnc is an independent medical education platform, supported with funding from Geron (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MDS 2020 | Targeted therapy for MDS
Drorit Merkel
• 5 Mar 2020
Drorit Merkel, MD, Cancer Biology Research Center, Tel Aviv University, Tel Aviv, Israel, outlines the importance of comprehending the genetic changes in high-risk myelodysplastic syndromes (MDS) to allow the development of targeted therapies. Also, Dr Merkel discusses current and upcoming treatment options for low and high-risk patients. This interview took place at the 2nd Regional Symposium on Myelodysplastic Syndromes (MDS 2020), held in Tel Aviv, Israel.
